Sumitomo Mitsui Trust Group
RXRX icon

Sumitomo Mitsui Trust Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$20.4M Sell
4,943,983
-567,704
-10% -$1.92M 0.01% 598
2026
Q2 		$20.2M Buy
5,511,687
+92,466
+2% +$308K 0.01% 619
2026
Q1 		$16.6M Sell
5,419,221
-801,804
-13% -$3.1M 0.01% 637
2025
Q4 		$25.4M Sell
6,221,025
-1,244,833
-17% -$6.17M 0.01% 604
2025
Q3 		$36.4M Sell
7,465,858
-701,887
-9% -$3.69M 0.02% 553
2025
Q2 		$41.3M Sell
8,167,745
-311,539
-4% -$1.53M 0.03% 507
2025
Q1 		$44.9M Sell
8,479,284
-501,317
-6% -$3.65M 0.03% 469
2024
Q4 		$60.7M Sell
8,980,601
-786,127
-8% -$5.29M 0.04% 399
2024
Q3 		$64.4M Sell
9,766,728
-220,302
-2% -$1.58M 0.04% 388
2024
Q2 		$74.9M Sell
9,987,030
-375,773
-4% -$3.28M 0.06% 332
2024
Q1 		$103M Buy
10,362,803
+1,159,023
+13% +$12.9M 0.07% 286
2023
Q4 		$90.7M Buy
9,203,780
+5,680,656
+161% +$40.5M 0.07% 314
2023
Q3 		$27M Buy
3,523,124
+2,685,724
+321% +$26.8M 0.02% 623
2023
Q2 		$6.26M Buy
837,400
+335,423
+67% +$2.35M ﹤0.01% 820
2023
Q1 		$3.35M Buy
501,977
+47,455
+10% +$376K ﹤0.01% 866
2022
Q4 		$3.5M Sell
454,522
-36,218
-7% -$355K ﹤0.01% 877
2022
Q3 		$5.22M Buy
490,740
+90,839
+23% +$920K ﹤0.01% 842
2022
Q2 		$3.26M Buy
+399,901
New +$2.68M ﹤0.01% 904
2022
Q1 		– Sell
-368,994
Closed -$6.32M – 1230
2021
Q4 		$6.32M Sell
368,994
-40,200
-10% -$756K ﹤0.01% 817
2021
Q3 		$9.42M Buy
409,194
+195,586
+92% +$5.54M 0.01% 781
2021
Q2 		$7.8M Buy
+213,608
New +$6.32M ﹤0.01% 816

Other funds holding RXRX

Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Green Alpha Advisors
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Raiffeisen Bank International
Raiffeisen Bank International Vienna, Austria $8.69B AUM 38.11% 1-Year Est. Return
Sowell Financial Services
Sowell Financial Services North Little Rock, Arkansas $3.12B AUM 22.73% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return
Values First Advisors
Values First Advisors Gray, Tennessee $213M AUM 20.51% 1-Year Est. Return
TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

Sumitomo Mitsui Trust Group's RXRX Position: Q3 2026 in Review

Sumitomo Mitsui Trust Group reduced its Recursion Pharmaceuticals (RXRX) stake by 10% in Q3 2026, selling an estimated $1.92M and leaving 4,943,983 shares worth $20.4M. The position accounts for 0.01% of the portfolio, ranked #598.

Sumitomo Mitsui Trust Group first reported a position in RXRX in Q2 2021 and has held it in 21 quarters since. The position peaked at $103M in Q1 2024. 83 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

  • Sumitomo Mitsui Trust Group held 4,943,983 shares of Recursion Pharmaceuticals worth $20.4M as of Q3 2026.
  • Sumitomo Mitsui Trust Group sold 567,704 Recursion Pharmaceuticals shares in Q3 2026, an estimated $1.92M.
  • Recursion Pharmaceuticals made up 0.01% of Sumitomo Mitsui Trust Group's portfolio in Q3 2026, its #598 holding.
  • Sumitomo Mitsui Trust Group first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Sumitomo Mitsui Trust Group's Recursion Pharmaceuticals position peaked at $103M in Q1 2024.
  • 83 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q3 2026, filed 29 Oct 2026.